GSK Investigator-sponsored studies programme


Belimumab 2019 ISS proposals (Cycle 1)


Currently accepting belimumab ISS proposals up to January 31st, 2019, with next review committee meeting in Q1-2019


Belimumab ISS Proposals can be submitted any time during the year, however GSK belimumab ISS committee will review them once a year (not applicable for other GSK ISS). In order to have your proposal reviewed by the next belimumab ISS committee (to be held in February 2019), please make sure to submit your proposal by 31st Jan, 2019. GSK belimumab ISS committee will communicate to investigators proposals that fall within current areas of interest and will be provisionally approved by March 2019. The investigators will then be requested to submit full protocol and ICF in English by April 2019. GSK will review these documents and come back to you with a final decision as soon as possible.

Summary of key dates:
-Submission of Proposal by Investigator: January 31, 2019
-Committee Review / Selection by GSK: February 2019
-Communication of Proposal of Interest to Investigators by GSK: March 31, 2019
-Submission of full Protocol and ICF by investigators: April 2019

GSK belimumab ISS committee is committed to the above review timelines, however, the review process might take longer for certain proposals.

The following areas are of interest to the Belimumab ISS Committee:
- BLyS inhibition with focus on other autoimmune diseases consistent with the belimumab anti- BLyS mechanism of action
- Use of anti- BLyS in combination with anti-CD20 in lupus and other mechanism of action compatible diseases
- Lupus patient perception and opinion about their treatment and life (with or without belimumab)
- Belimumab in lupus and other autoimmune diseases
- Association of biomarkers with patient stratification or clinical outcomes in lupus
- Use of belimumab in lupus in clinical practice
- Lupus disease state

Details and timelines described above are not applicable and cannot be used as reference for other GSK ISS areas of interest.

If you have any questions, please contact your local GSK Medical contact (e.g. MSL, others)

Click on "Submit Application" below to begin the process.

Powered by ideaPoint, Inc.

Posted: 01-22-2018
Created: 01-22-2018
Modified: 02-12-2019

Terms of use Accessibility Cookie policy Privacy
© 2001-2019 GlaxoSmithKline plc. All rights reserved. Registered in England and Wales No. 3888792.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.